Highlights
- Aggressive forms of B cell lymphomas like Burkitt lymphoma and diffuse large cell lymphoma, often do not respond to chemotherapy and kill its victims.
- An alternative therapy using microRNA miR-28 has been discovered that helps to inhibit the growth of these B cell lymphomas.
- MicroRNA miR-28 functions by regulating the differentiation and survival of B lymphocytes, blocking the growth of these cancers.
B-Cell Non-Hodgkin Lymphoma Risk in Middle Eastern Populations
Very few epidemiological studies have been conducted on B-cell non-Hodgkin lymphoma (B-NHL) in Middle Eastern populations.
Very few epidemiological studies have been conducted on B-cell non-Hodgkin lymphoma (B-NHL) in Middle Eastern populations.
‘The presence of microRNA miR-28 reduces the proliferative capacity and survival of mature B lymphocytes, thus preventing the progress of B cell lymphomas.’
Tweet it Now
Most of the non-Hidgkin lymphomas arise from mature B lymphocytes. The expression of microRNA miR-28 is lost in most lymphomas and re-establishing its expression slows tumor growth. This discovery establishes the therapeutic potential of synthetic miR-28 for inhibiting the growth of Burkitt lymphoma and diffuse large cell lymphoma and could lead to the development of the first miRNA therapy for the treatment of B cell lymphoma. This could provide the basis for human trials.
These miroRNAs (miRNAs) are small RNA molecules that regulate gene expression and has the ability to influence the biological and disease processes. The properties of miRNAs have attracted interest in their potential in the treatment of cancer.
Non-Hodgkin's Lymphoma Aided by Uracil DNA Glycosylase (UNG)
Uracil DNA glycosylase protects B cell DNA which allows the proliferation of activated B cells, highlighting a new target for non-Hodgkin’s lymphoma.
Uracil DNA glycosylase protects B cell DNA which allows the proliferation of activated B cells, highlighting a new target for non-Hodgkin’s lymphoma.
Around 60% of patients have very aggressive forms of the disease, such as Burkitt lymphoma or diffuse large cell lymphoma, and these patients often do not respond to chemotherapy or their disease relapses after treatment.
Advertisement
Genetic Mutations Influence Outcomes in Lymphoma Patients Who Undergo Transplants
Transplant recipients who were mutation carriers had a higher risk of developing a second blood cancer over the next 10 years compared with those lacking the mutation.
Transplant recipients who were mutation carriers had a higher risk of developing a second blood cancer over the next 10 years compared with those lacking the mutation.
MicroRNA miR-28
Advertisement
Everolimus Combined With R-CHOP Safe for Treating Diffuse Large B-Cell Lymphoma
The encouraging outcome, along with the worldwide availability of everolimus, make it potentially applicable to the large population of DLBCL patients.
The encouraging outcome, along with the worldwide availability of everolimus, make it potentially applicable to the large population of DLBCL patients.
The study demonstrates that miR-28 regulates the terminal differentiation and survival of B lymphocytes.
The cell differentiation plays an important role in generating memory B lymphocytes and highly specific plasma cells.
According to Dr. Ramiro, "the presence of miR-28 reduces the proliferative capacity and survival of mature B lymphocytes."
The research team discovered that miR-28 is often lost in lymphomas, and that re-establishing its expression slows tumor growth.
The study emphasizes the importance of conducting clinical trials of miR-28-based therapies to treat B cell lymphomas.
The study is published in Blood.
Reference
- Almudena R R. Ramiro et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood; (2017) doi.org/10.1182/blood-2016-08-731166
Source-Medindia
